Vitamin a derivative joins immunotherapy in fight against advanced lung cancer
NCT ID NCT04919369
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 29 times
Summary
This early-stage trial tests a combination of all-trans retinoic acid (ATRA), a drug made from vitamin A, and atezolizumab, an immunotherapy, in 18 adults with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand side effects. Participants must have already tried standard treatments, and the study does not aim to cure the disease but to control it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.